The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.

Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in response ...

Steroids are a huge part of bodybuilding and performance enhancement. However, it is very important to know the oral steroids ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and ... compared ...

Oral Controlled Release Drug Delivery Technology Market is anticipated to reach a valuation of about USD 68.4 billion by 2032 ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill, amycretin, ...

The first-in-human study has found that participants who received 50mg amycretin reduced their body weight by 10.4 per cent ...

Researchers found that a medicine called ferric carboxymaltose given in drip through the vein works faster and better than an ...

Researchers found that a medicine called ferric carboxymaltose given in drip through the vein works faster and better than an ...

Researchers found that a medicine called ferric carboxymaltose given in drip through the vein works faster and better than an ...